奥妥珠单抗治疗滤泡性淋巴瘤相关不良反应的研究进展

doi:10.19803/j.1672-8629.20250146

摘要/Abstract

摘要： 目的总结奥妥珠单抗治疗滤泡性淋巴瘤（FL）过程中相关不良反应的研究情况,为优化治疗方案和降低不良反应风险提供参考。方法通过文献检索与分析,对奥妥珠单抗的结构和特性、不良反应的类型、真实世界数据及其机制进行系统总结和论述。结果奥妥珠单抗作为一种经糖工程改造的人源化Ⅱ型抗CD20单克隆抗体,在B细胞恶性肿瘤中展现出更好的疗效和抗肿瘤活性,但其临床应用中可能产生输液相关反应、感染风险增加、肿瘤溶解综合征、骨髓抑制、乙型肝炎病毒再激活以及进行性多灶性脑白质病等不良反应,涉及免疫系统激活、细胞因子释放、B细胞耗竭、免疫监视功能受损等多方面因素。结论奥妥珠单抗在治疗FL中展现出显著的疗效,但其潜在的不良反应不容忽视,未来的研究需要深入探讨其不良反应机制,并制订有效的预防及管理策略,以优化治疗方案并降低不良反应风险。

关键词: 奥妥珠单抗, 滤泡性淋巴瘤, 抗CD20单克隆抗体, 药品不良反应, 机制研究

Abstract: Objective To summarize the research progress in adverse reactions associated with obinutuzumab used to treat follicular lymphoma (FL), and provide data for optimizing therapeutic regimens and mitigating the risks of adverse reactions. Methods Based on literature analysis, the structure, properties, types of adverse reactions, real-world data, and mechanisms of obinutuzumab were analyzed. Results As a glycoengineered type II humanized anti-CD20 monoclonal antibody, obinutuzumab demonstrated good efficacy and antitumor activity in B-cell malignancies. However, its clinical use might be associated with such adverse reactions as infusion-related reactions (IRR), increased risk of infection, tumor lysis syndrome (TLS), myelosuppression, hepatitis B virus (HBV) reactivation, and progressive multifocal leukoencephalopathy (PML), involving such factors as activation of the immune system, cytokine release, B-cell depletion, and impaired immune surveillance. Conclusion Obinutuzumab has shown significant efficacy in the treatment of FL. However, its potential adverse reactions deserve attention. Subsequent studies need to find out more about the mechanisms behind these adverse reactions and develop effective prevention and management strategies to optimize treatment regimens and reduce the risk of adverse reactions.

Key words: Obinutuzumab, Follicular Lymphoma, Anti-CD20 Monoclonal Antibody, Adverse Drug Reactions, Mechanism Research

中图分类号:

钟心茹, 杨德盈, 官堂明, 陈驹, 江东波. 奥妥珠单抗治疗滤泡性淋巴瘤相关不良反应的研究进展[J]. 中国药物警戒, 2025, 22(7): 831-835.

ZHONG Xinru, YANG Deying, GUAN Tangming, CHEN Ju, JIANG Dongbo. Research Progress in Adverse Reactions Caused by Obinutuzumab in the Treatment of Follicular Lymphoma[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 831-835.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20250146

https://zgywjj.magtechjournal.com/CN/Y2025/V22/I7/831

参考文献

[1] MERRYMAN R, MEHTAP O, LACASCE A.Advancements in the Management of Follicular Lymphoma: a Comprehensive Review[J]. Turkish Journal of Haematology, 2024, 41: 69-82.
[2] ZINZANI PL, MUNOZ J, TROTMAN J.Current and Future Therapies for Follicular Lymphoma[J]. Experimental Hematology & Oncology, 2024, 13(1): 87-87.
[3] LUMISH M, FALCHI L, IMBER BS, et al.How We Treat Mature B-cell Neoplasms (Indolent B-cell Lymphomas)[J]. Journal of Hematology & Oncology, 2021, 14(1): 5-5.
[4] ANDREW D, KATER AP, SHARMAN JP, et al.Obinutuzumab in the Treatment of B-Cell Malignancies: a Comprehensive Review[J]. Future Oncology, 2022, 18(26): 2943-2966.
[5] GUZAUSKAS GF, MASAQUEL A, THURESSON PO, et al.Obinutuzumab Plus Chemotherapy Followed by Obinutuzumab Monotherapy Is Cost-Effective vs Rituximab Plus Chemotherapy Followed by Rituximab Monotherapy for Previously Untreated Follicular Lymphoma Patients in the United States[J]. Leukemia & Lymphoma, 2019, 60(7): 1668-1676.
[6] MARCO B, LORENZO P, STEFANO M, et al.Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate-High Risk: a Cost-Effectiveness Analysis[J]. Clinicoecon Outcomes Res, 2021, 22(13): 661-671.
[7] TU MT, JAMIE TT, ARPAMAS S, et al.Healthcare Resource Utilization and Costs Associated with Obinutuzumab Plus Bendamustine Versus Rituximab Plus Bendamustine for First-Line Treatment of Follicular Lymphoma[J]. Blood, 2021, 138(S1): 3004.
[8] Chinese Society of Clinical Oncology. Lymphoma Diagnosis and Treatment Guidelines by the Chinese Society of Clinical Oncology (CSCO)(中国临床肿瘤学会淋巴瘤诊疗指南)[M]. Beijing: People's Medical Publishing House, 2022, 115.
[9] HORWITZ SM, ANSELL S, AI WZ, et al.T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology[J]. Natl Compr Canc Netw, 2022, 20(3): 285-308.
[10] KENSEI T, CHRISTIAN K, NAOKO O, et al.A Review of Obinutu-zumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies[J]. Advances In Therapy, 2017, 34(2): 324-356.
[11] MICHAEL C, ALEXIS MDF, MARIE P, et al.Direct Cell Death Induced by CD20 Monoclonal Antibodies on B Cell Lymphoma Cells Revealed by New Protocols of Analysis[J]. Cancers, 2023, 15(4): 1109.
[12] RYEOL JK, DONGHYUK L, YERIM K, et al.CD20/TNFR1 Dual-Targeting Antibody Enhances Lysosome Rupture-Mediated Cell Death in B Cell Lymphoma[J]. Cancer Immunology, Immunotherapy, 2022, 72(6): 1567-1580.
[13] JIANG ZY, WANG YJ, ZHANG Y, et al.Application of IL-6/IL-6R Inhibitors in Immuno-Inflammatory Skin Diseases[J]. Chinese Journal of Leprosy and Skin Diseases, 2024, 40(2): 145-149.
[14] MARIA C, STEFANO S, SAMMANTHA P.Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malig-nancies: Pathophysiology, Clinical Presentation, and Treatment[J]. International Journal of Molecular Sciences, 2021, 22(14): 7652.
[15] XING SS, ZHAO XQ, HU Y, et al.Observation and Nursing of Infusion Reactions in 145 Patients with Malignant Lymphoproliferative Disorders Receiving 90-Minute Rapid Intravenous Infusion of Ocaratu-zumab[J]. Military Nursing(军事护理), 2023, 40(10): 114-116.
[16] FREEMAN CL, MORSCHHAUSER F, SEHN L, et al.Cytokine Release in Patients with CLL Treated with Obinutuzumab and Possible Relationship with Infusion-Related Reactions[J]. Blood, 2015, 126(24): 2646-2649.
[17] MUCHA SR, RAJENDRAM P.Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications[J]. Current Oncology, 2023, 30(5): 5003-5023.
[18] ROTZ SJ, LEINO D, SZABO S, et al.Severe Cytokine Release Syndrome in a Patient Receiving PD-1-Directed Therapy[J]. Pediatric Blood & Cancer, 2017, 64(12): e26642.
[19] FREEMAN CL, DIXON M, HOUGHTON R, et al.Role of CD20 Expression and Other Pre-Treatment Risk Factors in the Development of Infusion-Related Reactions in Patients with CLL Treated with Obinutuzumab[J]. Leukemia, 2016, 30(8): 1763-1766.
[20] CIARA LF, MARK D, RICHARD H, et al.Risk Factors Associated with the Development of Infusion-Related Reactions in Patients with Chronic Lymphocytic Leukaemia Treated with Anti-CD20 Monoclonal Antibodies: Analysis of the CLL11 Study Datasetl[J]. Blood, 2014, 124(21): 3339.
[21] AMITAI I, GAFTER GA, SHARGIAN AL, et al.Obinutuzumab-Related Adverse Events: a Systematic Review and Meta-Analysis[J]. Hematological Oncology, 2020, 39(2): 215-221.
[22] LUPIA T, CORCIONE S, STAFFILANO E, et al.Disseminated Ente-rovirus Infection in a Patient Affected by Follicular Lymphoma Treated with Obinutuzumab: a Case Report and a Narrative Review of the Literature[J]. Medicina, 2024, 60(3): 495.
[23] LYZWA E, SOBIECKA M, LEWANDOWSKA K, et al.Prolonged SARS-CoV-2 Infection and Organizing Pneumonia in a Patient with Follicular Lymphoma, Treated with Obinutuzumab-Challenging Recognition and Treatment[J]. Viruses, 2023, 15(3): 693.
[24] SHU W, YANG Q, LE J, et al.Outcomes of COVID-19 in Patients with Obinutuzumab Compared with Patients with Rituximab: a Retrospective Cohort Study[J]. Virology Journal, 2024, 21(1): 212.
[25] LOONEY CM, SCHROEDER A, TAVARES E, et al.Obinutuzumab Effectively Depletes Key B-Cell Subsets in Blood and Tissue in End-Stage Renal Disease Patients[J]. Transplant Direct, 2023, 9(2): e1436.
[26] KEVIN B, JEROME SD, NICOLAS C.Ocrelizumab for the Treatment of Multiple Sclerosis[J]. Expert Review Of Neurotherapeutics, 2019, 19(2): 97-108.
[27] SCHWANER I, KUHN T, LOSEM C, et al.Low Incidence of Tumor Lysis Syndrome in Elderly Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax under Real-World Conditions: Results from the Prospective Observational VeRVe Study[J]. Annals Of Hematology, 2024, 103(6): 2013-2020.
[28] LEBLOND V, AKTAN M, FERRA CCM, et al.Safety of Obinutu-zumab Alone or Combined with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia in the Phase IIIb GREEN Study[J]. Haematologica, 2018, 103(11): 1889-1898.
[29] KUZNIEWSKA A, MAJERANOWSKI A, HENRY S, et al.The Acquisition of Complement-Dependent Cytotoxicity by the Type Ⅱ Anti-CD20 Therapeutic Antibody Obinutuzumab[J]. Cancers, 2023, 16(1): 49.
[30] SINA B, ANITA M, SIBEL K, et al.Complement-Dependent Activity of CD20-Specific IgG Correlates with Bivalent Antigen Binding and C1q Binding Strength[J]. Frontiers in Immunology, 2021, 11609941.
[31] GAO Y.Complement System in Anti-CD20 mAb Therapy for Cancer: a Mini-Review[J]. Int J Immunopathol Pharmacol, 2023, 37: 3946320231181464.
[32] LI Y, YAN YT, CHEN J, et al.Research on Prevention and Treatment of Adverse Reactions Related to Ocaratuzumab[J]. Chinese Journal Of Hospital Pharmacy Evaluation And Analysis(中国医院用药评价与分析), 2024, 24(7): 893-896.
[33] MATTHEW W, JOHN K, EMILEE T, et al.Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia[J]. Journal of the Advanced Practitioner in Oncology, 2022, 13(4): 400-415.
[34] MECHELFEKH Y, PONTRUCHER A, PAILLASSA J, et al.Obinutuzumab-Induced Acute Thrombocytopenia: Report of Two Cases and Review of Literature[J]. British Journal of Haematology, 2023, 202(1): 168-172.
[35] AREF Q, SAMIA A, STEPHANIE H, et al.A Case of Rituximab-Induced Acute Thrombocytopenia in a Patient with Splenic Marginal Zone Lymphoma and Chronic Hepatitis C Virus Infection[J]. The American Journal of Case Reports, 2019, 21(20): 201394-201397.
[36] ALABDULQADER RA, ALNASSER W, ALJUBRAN HJ, et al.A Case of Late-Onset Neutropenia in Relapsing-Remitting Multiple Sclerosis Following Ocrelizumab Therapy[J]. Cureus, 2024, 16(1): e51729.
[37] COHEN BA.Late-Onset Neutropenia Following Ocrelizumab Therapy for Multiple Sclerosis[J]. Neurology, 2019, 92(9): 435-436.
[38] YAZDY MS, CHESON BD.Impact of Obinutuzumab Alone and in Combination for Follicular Lymphoma[J]. Blood and Lymphatic Cancer, 2017: 773-783.
[39] ANTONIO BR, VICECONTE G, CALABRESE M, et al.Management of Hepatitis B Virus Prophylaxis in Patients Treated with Disease-Modifying Therapies for Multiple Sclerosis: a Multicentric Italian Retrospective Study[J]. Journal of Neurology, 2022, 269(6): 1-7.
[40] CHIU HY, CHIU YM, CHANG LN, et al.Predictors of Hepatitis B and C Virus Reactivation in Patients with Psoriasis Treated with Biologic Agents: a 9-Year Multicenter Cohort Study[J]. Journal of The American Academy Of Dermatology, 2021, 85(2), 337-344.
[41] GEORGE L, YANG ML, GRACE W, et al.APASL Clinical Practice Guideline on Hepatitis B Reactivation Related to the Use of Immun-osuppressive Therapy[J]. Hepatology International, 2021, 15(5): 1031-1048.
[42] OZOYA OO, CHAVEZ J, SOKOL L, et al.Optimizing Antiviral Agents for Hepatitis B Management in Malignant Lymphomas[J]. Annals of Translational Medicine, 2017, 5(3): 39.
[43] YAN WJM, HIN WAL, TUNG WKL, et al.Prevention and Management of Hepatitis B Virus Reactivation in Patients with Hematological Malignancies in the Targeted Therapy Era[J]. World Journal of Gastroenterology, 2023, 29(33): 4942-4961.
[44] ELISA G, ANTONIO G, GIANFRANCO F.HBV and Targeted Synthetic (ts)DMARDs: What Have We Learned from bDMARDs and tsDMARDs?[J]. RMD Open, 2020, 6(1): e001171.
[45] SOHEIL T, SEYED MA, SHAHNAZ S.Hepatitis B Reactivation during Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: a Comprehensive Review[J]. Hepatitis Monthly, 2016, 16(4): e35810.
[46] ANVARI S, TSOI K.Hepatitis B Virus Reactivation with Immun-osuppression: a Hidden Threat[J]. Journal of Clinical Medicine, 2024, 13(2): 393.
[47] XING C, YAFEI W, PANYUN L, et al.HBV Reactivation during the Treatment of Non-Hodgkin Lymphoma and Management Strategies[J]. Frontiers in Oncology, 2021, 11685706.
[48] VLATKO P, MARKO L, ZELJKO J, et al.Progressive Multifocal Leukoencephalopathy Developing after Obinutuzumab Treatment for Chronic Lymphocytic Leukemia[J]. Annals of Hematology, 2018, 98(6): 1509-1510.
[49] IVAN J, ILIJAS J, WOLFGANG F, et al.Immunology of Progressive Multifocal Leukoencephalopathy[J]. Journal of Neurovirology, 2015, 21(6): 614-622.
[50] HERVE DGDGM, DEKEYSER M, CHAVEZ HH, et al.Frequent Detection of IFN-Gamma-Producing Memory Effector and Effector T Cells in Patients with Progressive Multifocal Leukoencephalopathy[J].Frontiers in Immunology, 2024, 15: 1416074.
[51] DELGADO SR, FAISSNER S, LINKER RA, et al.Key Characteristics of Anti-CD20 Monoclonal Antibodies and Clinical Implications for Multiple Sclerosis Treatment[J]. Journal of Neurology, 2023, 271(4): 1515-1535.